Clinical Trial Update: Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib hydrochloride to reduce duodenal polyp burden in patients with familial adenomatous polyposis at risk of colon cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attenuated Familial Adenomatous Polyposis
• Familial Adenomatous Polyposis

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis | Phase 2 | Status: COMPLETED | Results posted: 2021-09-22